Taiwan Advance Bio-Pharmaceutical Inc. (TPEX:4186)
Taiwan · Delayed Price · Currency is TWD 10.80
+0.25 (2.37%)
May 8, 2026, 1:46 PM CST
TPEX:4186 Revenue
In the year 2025, Taiwan Advance Bio-Pharmaceutical had annual revenue of 364.79M TWD with 3.00% growth. Taiwan Advance Bio-Pharmaceutical had revenue of 169.35M in the half year ending June 30, 2025, with 31.46% growth.
Revenue
364.79M
Revenue Growth
+3.00%
P/S Ratio
2.65
Revenue / Employee
2.21M
Employees
165
Market Cap
967.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 364.79M | 10.62M | 3.00% |
| Dec 31, 2024 | 354.17M | 38.19M | 12.09% |
| Dec 31, 2023 | 315.98M | -2.25M | -0.71% |
| Dec 31, 2022 | 318.24M | 74.87M | 30.77% |
| Dec 31, 2021 | 243.36M | 7.79M | 3.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 736.59M |
| TCI GENE | 273.61M |
| GeneReach Biotechnology | 232.74M |
| Lukas Biomedical | 180.32M |
| NatureWise Biotech & Medicals | 180.29M |
| Holy Stone Healthcare | 47.51M |
| Neith | 36.15M |